| Gluconeogenesis in cancer: function and regulation of PEPCK, FBPase, and G6Pase Z Wang, C Dong Trends in cancer 5 (1), 30-45, 2019 | 223 | 2019 |
| Metabolic reprogramming in triple-negative breast cancer Z Wang, Q Jiang, C Dong Cancer biology & medicine 17 (1), 44, 2020 | 108 | 2020 |
| KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer C Liu, S Zheng, Z Wang, S Wang, X Wang, L Yang, H Xu, Z Cao, X Feng, ... Cancer Communications 42 (9), 828-847, 2022 | 52 | 2022 |
| Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer C Liu, L Yang, H Xu, S Zheng, Z Wang, S Wang, Y Yang, S Zhang, X Feng, ... BMC medicine 20 (1), 187, 2022 | 47 | 2022 |
| S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis Z Lu, S Zheng, C Liu, X Wang, G Zhang, F Wang, S Wang, J Huang, ... Clinical and translational medicine 11 (7), e459, 2021 | 38 | 2021 |
| ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells Y Lei, R Zang, Z Lu, G Zhang, J Huang, C Liu, Z Wang, S Mao, Y Che, ... Cell death & disease 11 (10), 853, 2020 | 31 | 2020 |
| S100A7 attenuates immunotherapy by enhancing immunosuppressive tumor microenvironment in lung squamous cell carcinoma C Liu, S Zheng, Z Lu, Z Wang, S Wang, X Feng, Y Wang, N Sun, J He Signal transduction and targeted therapy 7 (1), 368, 2022 | 6 | 2022 |
| Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators Z Wang, C Liu, S Zheng, Y Yao, S Wang, X Wang, E Yin, Q Zeng, C Zhang, ... Cancer Cell, 2024 | 1 | 2024 |
| Single-cell analysis reveals the potential mechanisms of pyrotinib resistance in non-small cell lung cancer X Wang, Y Li, R Jin, S Zheng, Y Luo, P Wu, Z Wang, Y Yao, N Sun, J He Signal transduction and targeted therapy 8 (1), 17, 2023 | 1 | 2023 |
| PD-L1 expression and smoke exposure as biomarkers for optimizing adjuvant therapy for patients with resected limited-stage small-cell lung carcinoma C Liu, Z Wang, Q Zeng, S Zheng, X Feng, Q Xue, N Sun, J He Genes & Diseases 10 (1), 48, 2023 | | 2023 |
